My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
DFM Foods recovers after recent sharp slide
Jun 16,2017

Meanwhile, the S&P BSE Sensex was up 31.04 points, or 0.1% at 31,106.77. The S&P BSE Small-Cap index was up 51.30 points, or 0.33% at 15,697.19.

High volumes were traded on the counter. On the BSE, 2,908 shares were traded on the counter so far as against the average daily volumes of 2,454 shares in the past one quarter. The stock had hit a high of Rs 1,299 and a low of Rs 1,205.95 so far during the day. The stock had hit a record high of Rs 2,433.60 on 17 June 2016 and a 52-week low of Rs 1,122 on 7 June 2017.

The stock had underperformed the market over the past one month till 15 June 2017, declining 28.12% compared with the Sensexs 2.49% rise. The scrip had also underperformed the market over the past one quarter declining 30.79% as against the Sensexs 5.71% rise. The scrip had also underperformed the market over the past one year declining 47.7% as against the Sensexs 16.27% rise.

The small-cap company has equity capital of Rs 10 crore. Face value per share is Rs 10.

Shares of DFM Foods had declined 11.52% in the preceding five trading sessions to settle at Rs 1,202.15 yesterday, 15 June 2017, from its close of Rs 1,358.70 on 8 June 2017.

DFM Foods net profit fell 68.5% to Rs 3.66 crore on 24.2% decrease in net sales to Rs 93.17 crore in Q4 March 2017 over Q4 March 2016.

DFM Foods is engaged in manufacturing and marketing of snack foods.

Powered by Capital Market - Live News

Pharma stocks witness selling pressure
Jun 16,2017

IPCA Laboratories (down 11.22%), Lupin (down 4.23%), Divis Laboratories (down 2.25%), Cadila Healthcare (down 2.14%), Cipla (down 1.78%), Sun Pharmaceutical Industries (down 1.75%), Dr Reddys Laboratories (down 1.23%), Strides Shasun (down 0.97%), Piramal Enterprises (down 0.56%) and Wockhardt (down 0.07%), edged lower. Glenmark Pharmaceuticals (up 0.31%), Alkem Laboratories (up 0.41%), GlaxoSmithKline Pharmaceuticals (up 0.75%) and Aurobindo Pharma (up 1.76%), edged higher.

The S&P BSE Sensex was up 34.56 points, or 0.11% at 31,110.29.

According to media reports, US President Donald Trumps administration is preparing an executive order aimed at lowering US drug costs. Officials in the administration will meet later today, 16 June 2017.

One policy being discussed for inclusion in the order is expressing support for value-based agreements, a drug industry-backed proposal in which pharmaceutical companies and health insurers develop arrangements to pay for products depending on how well they work, reports added.

A domestic brokerage reportedly said that this move could further create pricing pressure and hurt Indian pharma companies that are already facing regulatory issues and currency woes. The broker continued to remain cautious on the sector, reports added.

Powered by Capital Market - Live News

Aban Offshore leads gainers on BSEs A group
Jun 16,2017

Aban Offshore rose 12.96% at Rs 196.50. The stock topped the gainers in A group. On the BSE, 14.88 lakh shares were traded on the counter so far as against the average daily volumes of 1.42 lakh shares in the past two weeks.

Firstsource Solutions rose 5.56% at Rs 32.25. The stock was the second biggest gainer in A group. On the BSE, 5.04 lakh shares were traded on the counter so far as against the average daily volumes of 4.16 lakh shares in the past two weeks.

VA Tech Wabag rose 5.46% at Rs 727. The stock was the third biggest gainer in A group. On the BSE, 54,000 shares were traded on the counter so far as against the average daily volumes of 7,798 shares in the past two weeks.

GVK Power & Infrastructure rose 5% at Rs 6.30. The stock was the fourth biggest gainer in A group. On the BSE, 12.15 lakh shares were traded on the counter so far as against the average daily volumes of 11 lakh shares in the past two weeks.

Gujarat Mineral Development Corporation (GMDC) rose 4.97% at Rs 153. The stock was the fifth biggest gainer in A group. On the BSE, 1 lakh shares were traded on the counter so far as against the average daily volumes of 1.69 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Deepak Fertilisers gains after getting pending subsidy payment
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex was up 25.67 points, or 0.08% to 31,101.40.

On the BSE, 18,000 shares were traded in the counter so far, compared with average daily volumes of 4.27 lakh shares in the past one quarter. The stock had hit a high of Rs 273.35 and a low of Rs 268.50 so far during the day. The stock hit a record high of Rs 293.40 on 21 April 2017. The stock hit a 52-week low of Rs 150.20 on 24 June 2016.

The stock had outperformed the market over the past one month till 15 June 2017, rising 3.92% compared with 1.36% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 0.17% as against Sensexs 4.81% rise. The scrip had outperformed the market in past one year, rising 68% as against Sensexs 17.15% rise.

The small-cap company has equity capital of Rs 88.20 crore. Face value per share is Rs 10.

Deepak Fertilisers and Petrochemicals Corporation (DFPCL) said that the Department of Fertilisers (DoF), Ministry of Chemicals and Fertilisers, Government of India, has decided to release the pending Rs 310.52 crore fertiliser subsidy on a bank guarantee of equivalent amount. DoF had withheld the subsidy pending decision on recovery of alleged undue gain on account of supply of cheap gas.

Deepak Fertilisers and Petrochemicals Corporation (DFPCL) net profit surged 104.9% to Rs 46.62 crore on 4.7% decline in net sales to Rs 1050.50 crore in Q3 December 2016 over Q3 December 2015.

DFPCL has a multi-product portfolio spanning industrial chemicals, bulk and specialty fertilisers, farming diagnostics and solutions, technical ammonium nitrate, mining services and consulting and value added real estate.

Powered by Capital Market - Live News

Pennar Industries crawls up on plans to set up JV in US
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex fell 6.04 points or 0.02% to 31,069.69. The S&P BSE Small-Cap index rose 44.21 points or 0.28% to 15,690.10.

On the BSE, 62,673 shares were traded in the counter so far, compared with average daily volumes of 1.34 lakh shares in the past one quarter. The stock had hit a high of Rs 56.80 and a low of Rs 55.80 so far during the day. The stock had hit a 52-week high of Rs 58 on 13 June 2017. The stock had hit a 52-week low of Rs 39.50 on 21 November 2016.

The stock had outperformed the market over the past one month till 15 June 2017, rising 12.36% compared with 2.49% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 27.61% as against Sensexs 5.71% rise. The scrip had outperformed the market in past one year, gaining 24.72% as against Sensexs 16.27% rise.

The small-cap company has equity capital of Rs 60.17 crore. Face value per share is Rs 5.

Pennar Industries said that the company and Pennar Engineered Building Systems intend to set up a 50:50 joint venture (JV) in United States of America to supply their goods and services.

The JV will help both the companies to increase their addressable market and contribute to an increase in revenue and profitability.

On 13 June 2017, the company had said it received orders worth Rs 255 crore.

On a consolidated basis, net profit of Pennar Industries rose 10.8% to Rs 18.02 crore on 32.6% rise in net sales to Rs 464.87 crore in Q4 March 2017 over Q4 March 2016.

Pennar Industries offers specialized, engineered steel solutions. The company has a strong presence across growth sectors in India through four business units, steel products, tubes, industrial components and systems & projects, and its subsidiary companies, Pennar Engineered Building Systems, Pennar Renewables and Pennar Enviro.

Powered by Capital Market - Live News

Pennar Industries crawls up on plans to set up JV
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex fell 6.04 points or 0.02% to 31,069.69. The S&P BSE Small-Cap index rose 44.21 points or 0.28% to 15,690.10.

On the BSE, 62,673 shares were traded in the counter so far, compared with average daily volumes of 1.34 lakh shares in the past one quarter. The stock had hit a high of Rs 56.80 and a low of Rs 55.80 so far during the day. The stock had hit a 52-week high of Rs 58 on 13 June 2017. The stock had hit a 52-week low of Rs 39.50 on 21 November 2016.

The stock had outperformed the market over the past one month till 15 June 2017, rising 12.36% compared with 2.49% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 27.61% as against Sensexs 5.71% rise. The scrip had outperformed the market in past one year, gaining 24.72% as against Sensexs 16.27% rise.

The small-cap company has equity capital of Rs 60.17 crore. Face value per share is Rs 5.

Pennar Industries said that the company and Pennar Engineered Building Systems intend to set up a 50:50 joint venture (JV) in United States of America to supply their goods and services.

The JV will help both the companies to increase their addressable market and contribute to an increase in revenue and profitability.

On 13 June 2017, the company had said it received orders worth Rs 255 crore.

On a consolidated basis, net profit of Pennar Industries rose 10.8% to Rs 18.02 crore on 32.6% rise in net sales to Rs 464.87 crore in Q4 March 2017 over Q4 March 2016.

Pennar Industries offers specialized, engineered steel solutions. The company has a strong presence across growth sectors in India through four business units, steel products, tubes, industrial components and systems & projects, and its subsidiary companies, Pennar Engineered Building Systems, Pennar Renewables and Pennar Enviro.

Powered by Capital Market - Live News

Century Plyboards (India) gains after unit buys stake in Huesoulin Wood Processing Factory
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex was up 9.11 points, or 0.03% to 31,084.84.

On the BSE, 19,000 shares were traded in the counter so far, compared with average daily volumes of 27,035 shares in the past one quarter. The stock had hit a high of Rs 312.95 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 307.65 so far during the day. The stock hit a 52-week low of Rs 154.50 on 22 December 2016.

The stock had outperformed the market over the past one month till 15 June 2017, rising 14.04% compared with 1.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 25.62% as against Sensexs 4.81% rise. The scrip had also outperformed the market in past one year, rising 52.93% as against Sensexs 17.15% rise.

The mid-cap company has equity capital of Rs 22.22 crore. Face value per share is Re 1.

Century Plyboards (India) said its subsidiary, Century Ply (Singapore), in Singapore has acquired 49% stake in Huesoulin Wood Processing Factory Company, thereby making it an associate company. Huesoulin Wood Processing Factory Company is engaged in manufacturing and trading in plywood, veneer and all wood products and providing related services.

Net profit of Century Plyboards (India) rose 34.4% to Rs 55.91 crore on 9.3% rise in net sales to Rs 488.54 crore in Q4 March 2017 over Q4 March 2016.

Century Plyboards (India) is the largest seller of multi-use plywood and decorative veneers in the Indian organized plywood market.

Powered by Capital Market - Live News

Rane Holdings zooms 57% in twelve sessions
Jun 16,2017

Meanwhile, the S&P BSE Sensex was up 40.11 points, or 0.13% at 31,115.84. The S&P BSE Small-Cap index was up 58.76 points, or 0.38% at 15,704.65.

On the BSE, 6,675 shares were traded on the counter so far as against the average daily volumes of 4,854 shares in the past two weeks. The stock had hit a high of Rs 1,793.95 so far during the day, which is also its record high. The stock hit a low of Rs 1,640 so far during the day. The stock had hit a 52-week low of Rs 575 on 20 June 2016.

Shares of Rane Holdings surged 57% in twelve trading sessions to its current ruling price of Rs 1,763.35, from a close of Rs 1,123.10 on 30 May 2017.

Rane Holdings consolidated net profit spurted 98.9% to Rs 43.56 crore on 23.6% increase in total income to Rs 859.35 crore in Q4 March 2017 over Q4 March 2016.

Rane Holdings is the holding company of the Chennai-based Rane Group, an acknowledged leader in the manufacture of auto components.

Powered by Capital Market - Live News

RIL nudges higher after expanding partnership with BP
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex was up 1.74 points, or 0.01% to 31,077.47.

On the BSE, 4.07 lakh shares were traded in the counter so far, compared with average daily volumes of 66.56 lakh shares in the past one quarter. The stock had hit a high of Rs 1,395 and a low of Rs 1,370.10 so far during the day. The stock had hit a 52-week high of Rs 1,465 on 25 April 2017. The stock had hit a 52-week low of Rs 932 on 9 November 2016.

The stock had outperformed the market over the past one month till 15 June 2017, gaining 3.04% compared with 2.49% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 6.14% as against Sensexs 5.71% rise. The scrip had outperformed the market in past one year, rising 40.93% as against Sensexs 16.27% rise.

The large-cap company has equity capital of Rs 3251.57 crore. Face value per share is Rs 10.

Reliance Industries (RIL) and BP announced that they are moving forward to develop already-discovered deepwater gas fields, bringing new gas production for India. The two companies have agreed to deepen and expand their partnership to work jointly across a wide range of areas throughout Indias energy sector.

RIL and BP announced that they will award contracts to progress development of the R-Series deep water gas fields in Block KGD6 off the east coast of India. The R-series (D34) project is a dry gas development in water-depths of more than 2,000 metres, approximately 70 kilometres offshore. The R-series fields will be developed as a subsea tieback to the existing control and riser platform off Block KGD6. The project is expected to produce up to 12 million cubic metres (425 million cubic feet) of gas a day, coming on stream in 2020.

This is the first of three planned projects in Block KGD6 that are expected to be developed in an integrated manner, producing from about 3 trillion cubic feet of discovered gas resources. RIL and BP plan to submit development plans for the next two projects for Government approval before the end of 2017. Development of the three projects, with total investment of Rs 40000 crore ($6 billion), is expected to bring a total 30-35 million cubic metres (1 billion cubic feet) of gas a day new domestic gas production onstream, phased over 2020-2022.

India today consumes over 5 billion cubic feet a day of natural gas and aspires to double gas consumption by 2022. Gas production from the integrated development is expected to help reduce Indias import dependence and amount to over 10% of the countrys projected gas demand in 2022; benefiting India and domestic consumers at large.

Additionally, RIL and BP will expand their existing partnership for strategic cooperation on new opportunities across Indias energy sector. Under the agreement the two companies will jointly explore options to develop differentiated fuels, mobility and advanced low carbon energy businesses in India, as India transitions to a low-carbon world.

The companies expect to collaborate, in addition to the conventional transportation and aviation fuels retailing, on unconventional mobility solutions, addressing electrification, digitization and disruptive mobility trends. Together, these collaborations will seek to address the mobility needs of urban, rural/farm, industrial/commercial, and highway consumers in India, applying the leading capabilities of both partners.

In an historic partnership with RIL in 2011, BP took a 30% stake in multiple oil and gas blocks in India operated by RIL, including the producing Block KGD6. Block KGD6 participating interests are 60% RIL (operator), 30% BP and 10% by NIKO.

Gas produced over the life of these three new projects could generate up to $20 billion in import substitution (at current imported LNG prices) and employment of up to 20,000 skilled labour during the construction period over the next 5 years.

On a consolidated basis, net profit of RIL rose 11.5% to Rs 8053 crore on 42.1% rise in net sales to Rs 84823 crore in Q4 March 2017 over Q4 March 2016.

RIL is Indias largest private sector company. RILs activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and telecommunications.

Powered by Capital Market - Live News

Astrazeneca Pharma India gains after DCGI nod for asthma drug
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex was up 15.81 points, or 0.05% to 31,091.54.

On the BSE, 2,453 shares were traded in the counter so far, compared with average daily volumes of 4,977 shares in the past one quarter. The stock had hit a high of Rs 955.65 and a low of Rs 930 so far during the day. The stock hit a 52-week high of Rs 1,146.95 on 24 August 2016. The stock hit a 52-week low of Rs 909 on 27 February 2017.

The stock had underperformed the market over the past one month till 15 June 2017, falling 5.30% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 2.92% as against Sensexs 4.81% rise. The scrip had also underperformed the market in past one year, falling 14.72% as against Sensexs 17.15% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India said it received import and market permission in Form 45 (marketing authorization) from the Drug Controller General of India for fixed-dose combination (FDC) of Budesonide 320 n++g +Formoterol Fumarate Dihydrate 9 n++g inhalation powder.

FDC of Budesonide 320 n++g + Formoterol Fumarate Dihydrate 9 n++g inhalation powder (Symbicort Turbuhaler 320/9 n++g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting n++-agonist is appropriate and patients with moderate to severe chronic obstructive pulmonary disease (COPD) with frequent symptoms and a history of exacerbations.

Astrazeneca Pharma India reported net loss of Rs 2.88 crore in Q4 March 2017 as against net profit of Rs 0.56 crore in Q4 March 2016. Net sales declined 16.90% to Rs 110.95 crore in Q4 March 2017 over Q4 March 2016.

AstraZeneca Pharma India is a subsidiary of AstraZeneca Plc, UK. It covers manufacturing, sales and marketing activities of the company in India. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular and & metabolic diseases, oncology and respiratory.

Powered by Capital Market - Live News

SCI corrects on profit booking
Jun 16,2017

Meanwhile, the S&P BSE Sensex was up 90.82 points, or 0.29% to 31,166.55.

On the BSE, 1.71 lakh shares were traded in the counter so far, compared with average daily volumes of 4.58 lakh shares in the past one quarter. The stock had hit a high of Rs 85.85 and a low of Rs 83.35 so far during the day. The stock hit a 52-week high of Rs 92 yesterday, 15 June 2017. The stock hit a 52-week low of Rs 55.75 on 21 November 2016.

The stock had outperformed the market over the past one month till 15 June 2017, rising 4.91% compared with 1.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 31.59% as against Sensexs 4.81% rise. The scrip had also outperformed the market in past one year, rising 27.08% as against Sensexs 17.15% rise.

The mid-cap company has equity capital of Rs 465.80 crore. Face value per share is Rs 10.

Shares of Shipping Corporation of India (SCI) rose 18.78% in three trading sessions to settle at Rs 85.40 yesterday, 15 June 2017, from its close of Rs 71.90 on 12 June 2017.

The stock jumped 7.62% to settle at Rs 85.40 yesterday, 15 June 2017, on reports NITI Aayog has proposed strategic sale of about 26% stake in the company. According to reports, the core group of secretaries on disinvestment, headed by the cabinet secretary, discussed the proposal and has mandated the Shipping Ministry to find out legal hassles, if any, in the process. The proposal will soon go to the Cabinet Committee on Economic Affairs, reports added.

The government, at present, holds 63.75% stake in SCI. After the sale of 26% stake, the government holding in the company will come down to 37.75%. The sale of 26% stake could fetch about Rs 960 crore to the exchequer. The government has budgeted to raise Rs 15000 crore through strategic sale of PSUs this fiscal.

Net profit of Shipping Corporation of India declined 58.78% to Rs 92.36 on 5.09% decline in net sales to Rs 897.73 crore in Q4 March 2017 over Q4 March 2016.

Shipping Corporation of India in the largest Indian shipping company. The SCI also has substantial interests in various segments of the shipping trade.

Powered by Capital Market - Live News

Jindal Worldwide declines on profit booking
Jun 16,2017

Meanwhile, the S&P BSE Sensex was up 69.53 points, or 0.22% at 31,141.93. The S&P BSE Small-Cap index was up 82.87 points, or 0.53% at 15,728.76.

On the BSE, 22,000 shares were traded on the counter so far as against the average daily volumes of 30,000 shares in the past two-weeks. The stock had hit a high of Rs 650 so far during the day, which is also its record high. The stock had hit a low of Rs 599.35 so far during the day. The stock had hit a 52-week low of Rs 142.50 on 21 June 2016.

Jindal Worldwide had rallied 49.65% in the preceding three trading sessions to settle at Rs 637.15 yesterday, 15 June 2017, from its closing of Rs 425.75 on 12 June 2017.

Jindal Worldwides net profit spurted 106.5% to Rs 23.97 crore on 26.8% increase in net sales to Rs 368.02 crore in Q4 March 2017 over Q4 March 2016.

Jindal Worldwide is the leader in Indian textile Industries and is operating in Indian contingent as well as having its international collaboration and clients in north and South America to Europe, Africa and Middle-East Asia.

Powered by Capital Market - Live News

IPCA Lab slumps after USFDA bans drugs from three plants
Jun 16,2017

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P BSE Sensex was up 62.99 points, or 0.20% to 31,138.72.

On the BSE, 2.03 lakh shares were traded in the counter so far, compared with average daily volumes of 17,332 shares in the past one quarter. The stock had hit a high of Rs 468 and a low of Rs 437 so far during the day. The stock hit a 52-week high of Rs 656 on 5 April 2017. The stock hit a 52-week low of Rs 435 on 24 June 2016.

The stock had underperformed the market over the past one month till 15 June 2017, falling 5.75% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 6.55% as against Sensexs 4.81% rise. The scrip had also underperformed the market in past one year, rising 6.95% as against Sensexs 17.15% rise.

The mid-cap company has equity capital of Rs 25.24 crore. Face value per share is Rs 2.

IPCA Laboratories said that drugs manufactured at its facilities at SEZ Indore (Pithampur), Piparia (Silvassa) and Ratlam (Madhya Pradesh) have been banned from the US market by the US Food and Drug Administration (USFDA). The drug regulator cited violation of current good manufacturing norms for taking the step against the company. The USFDA has refused admission to all drugs made at the companys Pithampur and Silvassa facility. All drugs, except API Chloroquine Phosphate, made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said. The ban will continue until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (cGMP).

Net profit of IPCA Laboratories rose 34.8% to Rs 44.39 on 6% rise in net sales to Rs 665.80 crore in Q4 March 2017 over Q4 March 2016.

IPCA Laboratories is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) for various therapeutic segments.

Powered by Capital Market - Live News

Asian Paints slips ex-dividend
Jun 15,2017

Meanwhile, the S&P BSE Sensex was down 80.75 points or 0.26% at 31,075.16.

On the BSE, 46,000 shares were traded on the counter so far as against the average daily volumes of 1.14 lakh shares in the past two weeks. The stock had hit a high of Rs 1,152.10 and a low of Rs 1,134.70 so far during the day. The stock had hit a record high of Rs 1,230 on 13 October 2016 and a 52-week low of Rs 850.10 on 22 December 2016.

The stock had underperformed the market over the past one month till 14 June 2017, advancing 1.43% compared with the Sensexs 3.21% rise. The stock had, however, outperformed the market over the past one quarter, gaining 7.43% as against the Sensexs 5.82% rise. The scrip had underperformed the market over the past one year, surging 16.52% as against the Sensexs 18.03% rise.

The large-cap company has equity capital of Rs 95.92 crore. Face value per share is Rs 1.

The total dividend of Rs 7.65 per share comprises of final dividend of Rs 5.65 and a special dividend of Rs 2 per share.

Before turning ex-dividend, the stock offered a dividend yield of 0.66% based on the closing price of Rs 1,148.50 yesterday, 14 June 2017.

Asian Paints consolidated net profit rose 10.1% to Rs 479.61 crore on 7.8% rise in total income to Rs 3952.45 crore in Q4 March 2017 over Q4 March 2016.

Asian Paints is Indias leading paint company and ranked among the top ten decorative coatings companies in the world.

Powered by Capital Market - Live News

Jindal Worldwide soars over 43% in three sessions
Jun 15,2017

Meanwhile, the S&P BSE Sensex was down 75.24 points, or 0.24% to 31,080.67.

On the BSE, 1.01 lakh shares were traded in the counter so far, compared with average daily volumes of 25,957 shares in the past one quarter. The stock had hit a high of Rs 622 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 562 so far during the day. The stock hit a 52-week low of Rs 142.50 on 21 June 2016.

The stock had outperformed the market over the past one month till 14 June 2017, rising 19.92% compared with 1.87% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 91.64% as against Sensexs 5.31% rise. The scrip had also outperformed the market in past one year, rising 249.30% as against Sensexs 16.57% rise.

The small-cap company has equity capital of Rs 20.05 crore. Face value per share is Rs 10.

Shares of Jindal Worldwide have risen 43.53% in three trading sessions from its close of Rs 425.75 on 12 June 2017.

Net profit of Jindal Worldwide rose 106.5% to Rs 23.97 crore on 26.8% rise in net sales to Rs 368.02 crore in Q4 March 2017 over Q4 March 2016.

Jindal Worldwide is the leader in Indian textile Industries and is operating in Indian contingent as well as having its international collaboration and clients in north and South America to Europe, Africa and Middle-East Asia.

Powered by Capital Market - Live News